Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast Cancer

Sunil Verma, MD, MSEd, FRCPC
Published: Friday, Sep 05, 2014

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses clinical trial endpoints in metastatic breast cancer trials.

Verma says the two most talked about endpoints in metastatic breast cancer are overall survival (OS) and progression-free survival (PFS). PFS is marred by biases and may not get the complete picture of how patients will do long term. When compared to OS, PFS is considered to be substandard.

OS has always been considered the gold standard if researchers can impact the survival of the patients, Verma says. The challenge with OS as an endpoint is that it only tells researchers if the patient is alive or deceased while PFS tells researchers if the patient has progressed or not.

Verma says the journey in between the PFS and OS, termed the post-progression survival, is also a very important journey. Based on research presented at the 2014 ASCO Breast Cancer Symposium, looking at OS on its own is incomplete and researchers need to focus on the post-progression survival.

<<< View more from the 2014 Breast Cancer Symposium

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses clinical trial endpoints in metastatic breast cancer trials.

Verma says the two most talked about endpoints in metastatic breast cancer are overall survival (OS) and progression-free survival (PFS). PFS is marred by biases and may not get the complete picture of how patients will do long term. When compared to OS, PFS is considered to be substandard.

OS has always been considered the gold standard if researchers can impact the survival of the patients, Verma says. The challenge with OS as an endpoint is that it only tells researchers if the patient is alive or deceased while PFS tells researchers if the patient has progressed or not.

Verma says the journey in between the PFS and OS, termed the post-progression survival, is also a very important journey. Based on research presented at the 2014 ASCO Breast Cancer Symposium, looking at OS on its own is incomplete and researchers need to focus on the post-progression survival.

<<< View more from the 2014 Breast Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x